{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:58:32Z","timestamp":1784303912958,"version":"3.55.0"},"reference-count":45,"publisher":"Academy of Managed Care Pharmacy","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.18553\/jmcp.2020.26.11.1456","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T17:38:57Z","timestamp":1603993137000},"page":"1456-1462","source":"Crossref","is-referenced-by-count":7,"title":["The effectiveness and value of novel acute treatments for migraine"],"prefix":"10.18553","volume":"26","author":[{"given":"Foluso","family":"Agboola","sequence":"first","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Atlas","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Massachusetts General Hospital, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Touchette","sequence":"additional","affiliation":[{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Rind","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Pearson","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12482"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0907-6"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00990.x"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01945.x"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1607358"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.10.005"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1711803"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0910887"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414550416"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/head.12601"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0703-0"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70047-9"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"B20","unstructured":"Lipton RB, Conway CM, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the treatment of migraine: results from a phase 3, doubleblind, randomized, placebo-controlled trial, Study 301. Presented at: the 60th Annual Scientific Meeting of the American Headache Society; June 28-July 1, 2018; San Francisco, CA."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000079544"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000047960"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00394.x"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00593.x"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00004.x"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.1.156"},{"issue":"8","key":"B29","first-page":"970","volume":"22","author":"Havanka H","year":"2000","journal-title":"Naratriptan S2WB2004 Study Group. Clin Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.00238.x"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00315-3"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03044.x"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3803201.x"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868340"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3803184.x"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.04.003"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05178.x"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00617.x"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91554-0"},{"issue":"10","key":"B40","first-page":"748","volume":"38","author":"Tfelt-Hansen P","year":"1998","journal-title":"Rizatriptan 030 Study Group. Headache"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00783.x"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000116758"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00707.x"},{"issue":"2","key":"B44","first-page":"96","volume":"23","author":"Pini LA","year":"1995","journal-title":"The Oral Sumatriptan Italian Study Group. J Int Med Res"},{"issue":"11","key":"B45","first-page":"1343","volume":"39","author":"Brandes JL","year":"2019","journal-title":"Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T17:40:46Z","timestamp":1603993246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2020.26.11.1456"}},"subtitle":["A summary from the Institute for Clinical and Economic Review\u2019s Midwest Comparative Effectiveness Public Advisory Council"],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.18553\/jmcp.2020.26.11.1456"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2020.26.11.1456","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}